Visualitza per autor "Park, Keunchil"
Ara mostrant els elements 1-3 d 3
-
Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC
Nishio, Makoto; Felip Font, Enriqueta; Orlov, Sergey; Park, Keunchil; Yu, Chong-Jen; Tsai, Chun-Ming (Elsevier, 2020-04) -
Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451
Owonikoko, Taofeek; Park, Keunchil; Govindan, Ramaswamy; Ready, Neal; Reck, M.; Peters, S.; Navarro Mendivil, Alejandro (Lippincott Williams & Wilkins, 2021-04-20) -
Olmutinib in T790M-positive non–small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study
Park, Keunchil; Jӓnne, Pasi A.; Kim, Dong-Wan; Han, Ji-Youn; Wu, Ming-Fang; Lee, Jong-Seok; Felip Font, Enriqueta (Wiley, 2021-05-01)